Chardan Capital reiterated their sell rating on shares of Axovant Sciences Ltd (NYSE:AXON) in a report issued on Friday morning. They currently have a $3.00 target price on the biotechnology company’s stock.

Several other analysts also recently weighed in on AXON. BidaskClub downgraded shares of Axovant Sciences from a buy rating to a hold rating in a research note on Thursday, July 6th. Jefferies Group LLC started coverage on shares of Axovant Sciences in a research note on Monday, July 10th. They set a buy rating and a $40.00 price target for the company. Zacks Investment Research downgraded shares of Axovant Sciences from a hold rating to a sell rating in a research note on Tuesday, July 11th. Evercore ISI initiated coverage on shares of Axovant Sciences in a research note on Friday, September 8th. They set an outperform rating and a $30.00 price target for the company. Finally, Oppenheimer Holdings, Inc. reissued a buy rating and set a $30.00 price objective on shares of Axovant Sciences in a report on Monday, September 25th. Four analysts have rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Axovant Sciences has an average rating of Hold and a consensus target price of $14.13.

Shares of Axovant Sciences (AXON) opened at $5.40 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.01 and a current ratio of 6.01. Axovant Sciences has a 12 month low of $4.60 and a 12 month high of $27.98.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.12).

TRADEMARK VIOLATION NOTICE: “Chardan Capital Reiterates Sell Rating for Axovant Sciences Ltd (AXON)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/chardan-capital-reiterates-sell-rating-for-axovant-sciences-ltd-axon/1684868.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXON. Wells Fargo & Company MN grew its holdings in Axovant Sciences by 34.3% in the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock worth $335,000 after purchasing an additional 5,733 shares during the last quarter. American International Group Inc. grew its holdings in Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 998 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in Axovant Sciences in the first quarter worth $219,000. Bank of America Corp DE grew its holdings in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 2,072 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after purchasing an additional 197,600 shares during the last quarter.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.